Incretin Atlas › Trials › STEP-HFpEF DM
STEP-HFpEF DM
Semaglutide · HFpEF + obesity + T2D
Design
- Molecule(s)
- Semaglutide
- Population
- HFpEF + obesity + T2D
- Official title
- Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes
- Sponsor
- Novo Nordisk A/S
- Phase
- Phase 3
- Registry status
- completed · 2021-06 → 2023-10
- Participants
- 617
- Duration
- 52 weeks
- Registry
- NCT04916470
Outcomes in the indication
STEP-HFpEF DM Semaglutide · HFpEF + obesity + T2D · 52 weeks · n = 616 seed
KCCQ-CSS +7.3 points vs placebo
| Measure | Drug | Control | Difference (95 % CI) | Status |
|---|---|---|---|---|
| Body weight, percent change from baseline week 52 | −9.8 | −3.4 | −6.4 (−7.6 to −5.2) percentage points | verified |
| KCCQ clinical summary score, change from baseline week 52 | +13.7 | +6.4 | +7.3 (+4.1 to +10.4) points (0-100) | verified |
Verbatim quotes (2)
- Body weight, percent change from baseline
the mean percentage change in body weight was -9.8% with semaglutide and -3.4% with placebo (estimated difference, -6.4 percentage points; 95% CI, -7.6 to -5.2; P<0.001)
- KCCQ clinical summary score, change from baseline
The mean change in the KCCQ-CSS was 13.7 points with semaglutide and 6.4 points with placebo (estimated difference, 7.3 points; 95% confidence interval [CI], 4.1 to 10.4; P<0.001)
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: STEP-HFpEF DM. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/step-hfpef-dm/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.